You are here: Industry Insights > boehringer

News List

Boehringer pins hopes on novel psoriasis drug pharmaphorum
April 28, 2018
Boehringer Ingelheim has announced bold plans to bring a generation of new medicines to market in the coming years.
Boehringer Ingelheim Ups Venture Fund to €250M biospace
January 04, 2018
Boehringer Ingelheim Demonstrates Continuous Commitment to Its Venture Fund and Fostering Innovation by More than Doubling Funding to 250 M€
Boehringer Inks €627.5M Deal With GlaxoSmithKline Spinout biospace
December 19, 2017
Boehringer Ingelheim tied up a schizophrenia drug under development by U.K.-based Autifony Limited, a 2011 spinout of GlaxoSmithKline, in a deal that could be worth up to €627.5 million (about $740 million).
New CNS partnership between Boehringer and Autifony pharmatimes
December 19, 2017
Germany’s Boehringer Ingelheim and Cambridge, UK-based Autifony Therapeutics have announced a new collaboration focused on a novel therapeutic approach to a range of CNS disorders.
Boehringer celebrates EU approval of Humira biosimilar pharmafile
November 15, 2017
Boehringer Ingelheim has announced that Cyltezo, its biosimilar of Abbvie’s Humira, has received marketing authorisation approval from the European Commission, confirming that is comparable in safety and efficacy to its originator produc
Boehringer, Dicerna pen $201M pact to hit NASH with RNAi fiercebiotech
November 03, 2017
Boehringer Ingelheim has put up $201 million (€173 million) to work with Dicerna Pharmaceuticals on RNAi treatments for NASH and other chronic liver diseases.
Boehringer and Geisinger to develop risk-prediction model for type 2 diabetes health outcomes pharmaceufical-technology
September 28, 2017
The three type 2 diabetes-related common health outcomes include cardiovascular death, kidney failure and hospitalisation for heart failure.
Boehringer collaborates with Gubra to develop next generation obesity treatments biospectrumasia
September 12, 2017
As per the deal, Boehringer can access Gubra’s expertise in the design, synthesis and preclinical testing of therapeutic peptides
Boehringer and Gubra collaborate to discover peptide compounds for obesity treatment pharmaceufical-technology
September 11, 2017
Germany-based Boehringer Ingelheim has entered a collaboration and licensing agreement with Danish biotech company Gubra to develop new peptide compounds to treat obesity.
Boehringer’s Humira biosimilar wins US green light pharmatimes
August 31, 2017
US regulators have approved Boehringer Ingelheim’s Cyltezo, a biosimilar to AbbVie’s Humira, in a pre-filled syringe for the treatment of multiple chronic inflammatory diseases

Previous page 1 2 3 4 5 6 Next page